AnGes MG Grants MTPC Marketing Rights for HGF Gene Treatment for Peripheral Vascular Diseases in Japan

June 24, 2015
AnGes MG said on June 23 that it has entered into a license deal with Mitsubishi Tanabe Pharma Corporation (MTPC) for exclusive marketing rights for its hepatocyte growth factor (HGF) gene treatment AMG0001 (beperminogene perplasmid) in Japan for the treatment...read more